Sante Capital Fund’s Arcus Biosciences RCUS Stock Holding History

Sante Capital Fund’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-24,139	Closed	-$842K	–	22
2021 Q3	$842K	Buy	+24,139	New	+$751K	0.78%	24

Other funds holding RCUS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sante Capital Fund's RCUS Position: Q4 2021 in Review

Sante Capital Fund sold out of Arcus Biosciences (RCUS) in Q4 2021, closing a stake of 24,139 shares — an estimated $842K sold.

Sante Capital Fund first reported a position in RCUS in Q3 2021 and held it in 1 quarter. The position peaked at $842K in Q3 2021. 142 funds tracked by Wall St. Rank hold RCUS as of Q4 2021.

Sante Capital Fund reported no remaining Arcus Biosciences position as of Q4 2021 after selling out during the quarter.
Sante Capital Fund sold 24,139 Arcus Biosciences shares in Q4 2021, an estimated $842K.
Sante Capital Fund first reported a position in Arcus Biosciences in Q3 2021 and held it in 1 quarter.
Sante Capital Fund's Arcus Biosciences position peaked at $842K in Q3 2021.
142 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2021.

Based on Sante Capital Fund's 13F filing for Q4 2021.